Lapatinib in combination with capecitabine plus oxaliplatin (CapeOx) in HER2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma (AC): The TRIO-013/LOGiC Trial.
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: J. Randolph Hecht, Yung-Jue Bang, Shukui Qin, Hyun-Chul Chung, Jian-Ming Xu, Joon Oh Park, Krzysztof Jeziorski, Yaroslav Shparyk, Paulo M. Hoff, Alberto F. Sobrero, Pamela Salman, Jin Li, Svetlana Protsenko, Marc E. Buyse, Karen Afenjar, Tomomi Kaneko, Allison Kemner, Sergio Santillana, Michael F. Press, Dennis J. Slamon
Institutions: University of California, Los Angeles, Seoul National University Hospital, Yonsei University, Severance Hospital, Academy of Military Medical Sciences, Samsung Medical Center, Sungkyunkwan University, The Maria Sklodowska-Curie National Research Institute of Oncology, Instituto do Câncer do Estado de São Paulo, Ospedale Policlinico San Martino, Fundación Arturo López Pérez, Fudan University Shanghai Cancer Center, Institute of Oncology NN Petrov, International Drug Development Institute (Belgium), GlaxoSmithKline (United Kingdom), GlaxoSmithKline (Brazil), USC Norris Comprehensive Cancer Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2241983385